Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00075608 · ClinicalTrials.gov registry record · Phase 2
2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis
A Phase 2 study, sponsored by Boston Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00075608: Clinical Trial Phase 2 study, sponsored by Boston Medical Center.
NCT00075608 is a Phase 2 study that was terminated before completion, run by Boston Medical Center. The registered enrollment target is 12 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00075608, a Phase 2 study, was terminated before completion, sponsored by Boston Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of plasma cells, either by killing the cells or by stopping them from dividing. Having a stem cell transplant to replace the blood-forming cells destroyed by chemotherapy, allows higher doses of chemotherapy to be given so that more plasma cells are killed. By reducing the number of plasma cells, the disease may progress more slowly. PURPOSE: This phase II trial is studying how well autologous stem cell transplant works in treating patients with persistent or recurrent primary systemic (AL) amyloidosis.
Primary Outcome
Feasibility and tolerability will be evaluated based on participants completing second transplant with tolerable adverse events
Interventions
- PROCEDURE autologous stem cell transplantation
- DRUG melphalan
- BIOLOGICAL filgrastim
- PROCEDURE stem cell infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2001-08 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
Why NCT00075608 stopped before completion
NCT00075608 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 4 interventions - of which autologous stem cell transplantation is the first listed.
NCT00075608 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00075608 about?
NCT00075608 is a clinical study titled "2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis". RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of plasma cells, either by killing the cells or by stopping them from dividing. Having a stem cell transplant to replace the blood-forming cells destroyed by chemotherapy, allows higher doses of chemotherapy to be given ...
What is the current status of trial NCT00075608?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2001-08. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00075608?
The interventions under investigation include: autologous stem cell transplantation (PROCEDURE), melphalan (DRUG), filgrastim (BIOLOGICAL), stem cell infusion (PROCEDURE).
Who is sponsoring clinical trial NCT00075608?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00075608's enrollment target sits among peer trials
12 1948th of 2000 higher than 34 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia